Geographic concentration supply chain risk in pharma rarely sits where procurement teams look for it. Your API supplier may be in India, Ireland, or New Jersey, but the key starting materials (KSMs) behind that API often trace back to a single country. According to ITIF’s August 2026 analysis of U.S. API dependence, nearly 41 percent of KSMs used in U.S.-approved APIs are produced only in China.
The direct answer: if you measure concentration only at tier 1, you are measuring the wrong thing. Pharma procurement teams need to map country-of-origin exposure down to the KSM and intermediate level, put a dollar figure on each chokepoint, and act on sourcing and contract terms before a trade action or a single plant failure makes the decision for them.
Why Tier-1 Data Understates Geographic Concentration Risk in Pharma
On paper, U.S. API supply looks diversified. USP’s analysis of API manufacturing volume finds that India and the EU account for more than half of the API volume behind U.S. prescription medicines, with China contributing about 8 percent directly.
Go one tier deeper and the picture changes. India’s government think tank NITI Aayog found that India imported $7.4 billion in APIs in 2025, and China supplied between 65 and 86 percent of the top import categories. ITIF adds that the U.S. imports 90 percent of its ibuprofen from China.
A supplier map that stops at the API manufacturer’s address shows where risk gets relabeled, not where it lives.
Tier 2 visibility is the real diversification test
Two “different” API suppliers in Hyderabad and Gujarat can share the same Chinese KSM producer. That is not dual sourcing. It is one point of failure with two invoices.
Geopolitical Supply Chain Risk Is Now on a Policy Calendar
Trade policy has put concentration risk on a calendar. The April 2026 Section 232 proclamation on pharmaceuticals and pharmaceutical ingredients applied tariffs to patented drugs and their ingredients. Generics and biosimilars were left out for now, but the Commerce Secretary must report within a year on whether to act on generics and their associated ingredients.
Per CBP’s implementation guidance, duties for all remaining affected companies took effect September 29, 2026. A week earlier, the Commerce Department’s BIS defined zero-rate specialty categories and 19 eligible jurisdictions, including the EU, Japan, the UK, India, and Vietnam. The supply chain tariff impact on procurement now depends on where product and ingredients originate, which makes origin data a cost input, not a compliance footnote.
Concentration turns into shortages quickly
US active drug shortages rose to 227 in Q2 2026, the third straight quarterly increase, and 48 percent of new 2026 shortages involved sole-source products, according to ASHP and University of Utah data reported by AJMC. When one site or region goes down, there is no slack.
What Good Looks Like: From Concentration Maps to Concrete Actions
Chain Verity (chainverity.ai) monitors suppliers continuously across 200+ financial signals at tier 1, 2, and 3, and translates concentration into working capital at risk in dollars. The output is not a heat map. It is recommendations your team can act on.
Avoiding disruption before it starts
- Diversification triggers: when a large share of a product family’s KSM volume traces to one country and that upstream producer’s financial signals weaken, Chain Verity flags which molecules to begin qualifying a second source for, and when. Because adding a source in pharma requires regulatory filings, that clock has to start early.
- Contingency and dual-sourcing timing: when to build safety stock or activate a qualified alternate, ideally ahead of the Commerce report on generics.
- Early supplier engagement: which API makers to approach now about KSM origin plans, while you still have leverage.
Restructuring contracts around live risk data
- Exclusivity clauses: loosen exclusivity where upstream chemistry is concentrated in one region, so you can qualify alternates without breach.
- Minimum volume commitments: allow volume to shift to a secondary source when risk thresholds are crossed.
- Pricing indexation: define tariff pass-through tied to declared API and KSM origin.
- Audit and reporting rights: require KSM origin disclosure and advance notice of upstream source changes.
- Termination and step-in triggers: link them to FDA warning letters, import alerts, or sustained financial deterioration.
Pharma teams that want to shape this approach can join the Chain Verity design partner program.
Frequently Asked Questions
Q: What is geographic concentration supply chain risk in pharma?
A: It is the exposure created when a large share of an API, intermediate, or key starting material comes from one country or region. In pharma it often hides at tier 2 or 3, below the API supplier you contract with.
Q: How do I find out where my API’s key starting materials come from?
A: Start by requiring KSM and intermediate origin disclosure in supplier questionnaires and contracts. Chain Verity then maps these sub-tier links and flags when several suppliers depend on the same upstream producer.
Q: Do the Section 232 pharmaceutical tariffs apply to generic drugs?
A: Not at present. The April 2026 proclamation covers patented drugs and their ingredients and excludes generics and biosimilars, but it requires the Commerce Secretary to report within a year on whether generics and their ingredients should be covered.
Q: How does Chain Verity reduce geographic concentration risk?
A: Chain Verity quantifies exposure in dollars across tier 1 to 3 suppliers and turns it into specific actions: which molecules to dual-source and when, when to build contingency stock, and which contract clauses to renegotiate before renewal.
